IVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inventiva SA (IVA) is not a good buy at the moment for a beginner investor with a long-term strategy. The stock exhibits bearish technical indicators, lacks positive trading signals, and has no recent news or financial data to support a strong bullish case. Additionally, the stock's short-term trend suggests potential downside.
The MACD histogram is negative and contracting, RSI is neutral at 22.31, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels show the stock is trading near support (S1: 3.549).
Hedge funds are significantly increasing their positions, with a 681.82% increase in buying over the last quarter. Analysts maintain a Buy rating, citing the potential of lanifibranor (Lani) in addressing liver disease and T2D MASH populations.
The stock exhibits bearish technical indicators, no recent news or financial updates, and no significant insider or congress trading activity. Short-term stock trend analysis predicts a likely decline of -1.28% in the next day and -2.56% in the next week.
No financial data available for assessment.
Stifel has lowered the price target from $17 to $15 while maintaining a Buy rating. Analysts are optimistic about the potential of lanifibranor (Lani) in addressing liver disease and T2D MASH populations, but the pivotal trial results are not expected until Q4 2026.
